Atrial fibrillation.

By Rahul Wadke. Disease-a-month : DM, 2022

1,738 citations recorded by the source corpus.

The primary treatment of atrial fibrillation involves rate control, prevention of thromboembolic events and restoring the heart to sinus rhythm. Control of atrial fibrillation is achieved through pharmacological treatment and cardioversion. Refractory atrial fibrillation may benefit from surgical approaches to treatment. Atrial fibrillation is a disease that affects individuals in later years, however, rarely may affect children. A new diagnosis of atrial fibrillation requires investigation into possible reversible causes as a first approach to therapy. Prevention of atrial fibrillation is highlighted as a way to lower the risks associated with complications of atrial fibrillation and stroke, such as substance abuse and obesity. New guidelines influencing how atrial fibrillation is understood and treated, including newer pharmacological agents, are discussed.

Subfields: Cardiology and Cardiovascular Medicine, Immunology

View Paper: https://www.semanticscholar.org/paper/f7f8d83a9068de95e399fe00f35a9a492dd850fd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. G. Clifford
2. W. Dichtl
3. T. Senoner
4. Gerhard Hindricks
5. Mohammed Saeed

In Immunology

1. W. Dichtl
2. T. Senoner

Citations in the corpus

• 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. (2012, background): “Also, considerably more clinical experience has been gathered in the fields of anticoagulation, atrial appendage occlusion, antiarrhythmic drug use for cardioversion and rhythm control, and left atrial ablation.(10) These five areas form the bulk of the revisions to our recommendations.”
• AF Classification from a Short Single Lead ECG Recording: the PhysioNet/Computing in Cardiology Challenge 2017 (2017, background): “Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 1-2% of the general population [1] and is associated with significant mortality and morbidity through association of risk of death, stroke, heart failure and coronary artery disease, etc.”
• Purification and identification of novel angiotensin-I converting enzyme (ACE) inhibitory peptides from cultured marine microalgae (Nannochloropsis oculata) protein hydrolysate (2013, background): “According to the WHO reports in 2011, CVDs are increasing and present a challenge to the health of the world population.”
• Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target? (2019, background): “The risk for atrial fibrillation increases with aging, occurring in fewer than 1% of persons aged 60 to 65 years but in 8% to 10% of those older than 80 years [88].”
• 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. (2014, neutral): “AF indicates atrial fibrillation; CHADS2, Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, Prior Stroke or TIA or Thromboembolism (doubled); CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥75 years (doubled), Diabetes mellitus, Prior Stroke or TIA or thromboemboli”